Bionano Genomics (BNGO) stock tumbled 5.02% in intraday trading on Friday, as investors reacted to an earnings preview that projected losses and a significant drop in revenue for the company's upcoming financial report.
According to the earnings preview, Bionano Genomics, based in San Diego, California, is expected to report a 42.2% decrease in revenue to $6.2 million for the quarter ending December 31, 2024, compared to $10.72 million in the same period a year ago. The mean estimate from analysts suggests the company will post a loss of $6.00 per share.
The bearish sentiment surrounding Bionano Genomics' earnings prospects appears to have weighed heavily on the stock's performance. With analysts maintaining a "hold" rating on the shares and a median 12-month price target of $60.00, investors may be exercising caution ahead of the company's financial results release, scheduled for March 3, 2025 (estimated).
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。